This article is more than 5 years old. Information may no longer be current.

Dermata Therapeutics announces new board member

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Dermata Therapeutics announced the appointment of Wendell Wierenga, PhD, to its board of directors, according to a press release.

Wierenga most recently served as executive vice president of research and development at Santarus (acquired by Salix Pharmaceuticals). Before that, he served as executive vice president of research and development at both Ambit Biosciences and Neurocrine Biosciences.

“We are very excited to have Wendell be part of our board of directors. I have worked with Wendell for many years and believe he will be an invaluable asset in helping with the development of our programs from his years of experience in biotech,” Gerry Proehl, president, chief executive officer and director of Dermata Therapeutics, said in the release.

Reference: www.dermatarx.com